{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:01Z","timestamp":1793262001805,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.jlr.2021.100062","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T15:51:17Z","timestamp":1614959477000},"page":"100062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Lipoprotein metabolism in familial hypercholesterolemia"],"prefix":"10.1016","volume":"62","author":[{"given":"K\u00e9vin","family":"Chemello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Nafr\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5912","authenticated-orcid":false,"given":"Dirk","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2021.100062_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1073\/pnas.72.3.1092","article-title":"Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor","volume":"72","author":"Goldstein","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2021.100062_bib2","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib3","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib4","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jacc.2017.11.028","article-title":"Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes","volume":"71","author":"D\u2019Erasmo","year":"2018","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/hrt.44.4.361","article-title":"Cadiovascular complications of homozygous familial hypercholesterolaemia","volume":"44","author":"Allen","year":"1980","journal-title":"Br. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.jlr.2021.100062_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","article-title":"Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France","volume":"257","author":"Bruckert","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib9","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib10","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","article-title":"Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes","volume":"36","author":"Nanchen","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jacc.2017.08.009","article-title":"Genetically confirmed familial hypercholesterolemia in patients with acute coronary syndrome","volume":"70","author":"Amor-Salamanca","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/CIRCULATIONAHA.118.033470","article-title":"Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke","volume":"138","author":"Sabina","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib14","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)","volume":"36","author":"P\u00e9rez de Isla","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib15","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/eurheartj\/ehl113","article-title":"Diagnosing familial hypercholesterolaemia: the relevance of genetic testing","volume":"27","author":"van Aalst-Cohen","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","article-title":"Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"13","author":"Akioyamen","year":"2019","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100062_bib18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti Sarah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijcard.2015.08.146","article-title":"Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia","volume":"201","author":"Chan","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12944-020-01428-y","article-title":"Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania","volume":"20","author":"Vlad","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jlr.2021.100062_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40618-018-0959-0","article-title":"Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes","volume":"42","author":"Sun","year":"2019","journal-title":"J.\u00a0Endocrinol. Invest."},{"key":"10.1016\/j.jlr.2021.100062_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jlr.2021.100062_bib24","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2021.100062_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmedgenet-2016-104054","article-title":"The UCL low-density lipoprotein receptor gene variant database: pathogenicity update","volume":"54","author":"Leigh","year":"2017","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib26","doi-asserted-by":"crossref","first-page":"574474","DOI":"10.3389\/fgene.2020.574474","article-title":"Genetics of familial hypercholesterolemia: new insights","volume":"11","author":"Vrablik","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: Mutational Analysis of a Membrane Protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib28","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/S0021-9258(19)42341-7","article-title":"Binding and degradation of low density lipoproteins by cultured human fibroblasts comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia","volume":"249","author":"Goldstein","year":"1974","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100062_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0021-9150(97)06086-3","article-title":"Surface expression of low density lipoprotein receptor in EBV-transformed lymphocytes: characterization and use for studying familial hypercholesterolemia","volume":"131","author":"Chan","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/clinchem\/44.5.966","article-title":"Flow cytometry with a monoclonal antibody to the low density lipoprotein receptor compared with gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia","volume":"44","author":"Raungaard","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jlr.2021.100062_bib31","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.D017772","article-title":"An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations","volume":"52","author":"Romano","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cca.2008.10.010","article-title":"A\u00a0novel method for determining functional LDL receptor activity in familial hypercholesterolemia: Application of the CD3\/CD28 assay in lymphocytes","volume":"400","author":"Tada","year":"2009","journal-title":"Clinica Chim. Acta"},{"key":"10.1016\/j.jlr.2021.100062_bib33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/j.1552-4604.1997.tb04327.x","article-title":"Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia","volume":"37","author":"Chan","year":"1997","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.jlr.2021.100062_bib34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0009-9120(92)80019-D","article-title":"Assessment of functional low-density-lipoprotein receptors on lymphocytes by a simplified method using culture medium with lipoprotein-free fetal calf serum and pravastatin","volume":"25","author":"Sakuma","year":"1992","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jlr.2021.100062_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112677","article-title":"Advantages and versatility of fluorescence-based methodology to characterize the functionality of LDLR and class mutation assignment","volume":"9","author":"Etxebarria","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jlr.2021.100062_bib36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2012.08.017","article-title":"In\u00a0vitro functional characterization of missense mutations in the LDLR gene","volume":"225","author":"Silva","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib37","doi-asserted-by":"crossref","first-page":"8349","DOI":"10.1074\/jbc.AAC119.009121","article-title":"Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions","volume":"294","author":"Wang","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100062_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/humu.22721","article-title":"Functional characterization and classification of frequent low-density lipoprotein receptor variants","volume":"36","author":"Etxebarria","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jlr.2021.100062_bib39","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1073\/pnas.84.19.6919","article-title":"Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding","volume":"84","author":"Innerarity","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jlr.2021.100062_bib40","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/hmg\/ddt573","article-title":"Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia","volume":"23","author":"Alves","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.atherosclerosis.2018.06.819","article-title":"Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia","volume":"277","author":"Alves","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jcb.240250204","article-title":"A\u00a0requirement for cholesterol and its structural features for a human macrophage-like cell line","volume":"25","author":"Esfahani","year":"1984","journal-title":"J.\u00a0Cell Biochem."},{"key":"10.1016\/j.jlr.2021.100062_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1194\/jlr.M000422","article-title":"Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor","volume":"51","author":"Huang","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib45","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade Thematic Review Series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases","volume":"53","author":"Lambert","year":"2012","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin\u2013kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100062_bib47","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/ATVBAHA.120.314482","article-title":"Novel PCSK9 (proprotein convertase subtilisin kexin type 9) variants in patients with familial hypercholesterolemia from Cape Town","volume":"41","author":"Huijgen","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib48","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"Cameron","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","article-title":"Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia","volume":"14","author":"Sun","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib50","doi-asserted-by":"crossref","first-page":"15282","DOI":"10.1038\/s41598-017-15543-x","article-title":"Identification and in\u00a0vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia","volume":"7","author":"Di Taranto","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jlr.2021.100062_bib51","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.jacc.2015.08.871","article-title":"Characterization of the first PCSK9 gain of function homozygote","volume":"66","author":"Alves","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2019.08.020","article-title":"The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9","volume":"289","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib53","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jlr.2021.100062_bib54","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1242\/jcs.03217","article-title":"The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH","volume":"119","author":"Maurer","year":"2006","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.jlr.2021.100062_bib55","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1172\/JCI0216445","article-title":"Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1","volume":"110","author":"Eden","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100062_bib56","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1093\/hmg\/11.24.3019","article-title":"Molecular mechanisms of autosomal recessive hypercholesterolemia","volume":"11","author":"Wilund","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib57","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/ATVBAHA.116.307493","article-title":"Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia\u2014brief report","volume":"36","author":"Thedrez","year":"2016","journal-title":"Arteriosclerosis, Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib58","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1111\/ajt.12961","article-title":"Transmission of LDLR mutation from donor through liver transplantation resulting in hypercholesterolemia in the recipient","volume":"14","author":"Nikkil\u00e4","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jlr.2021.100062_bib59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.ejhg.5200152","article-title":"Concentrations of the atherogenic Lp(a) are elevated in familial hypercholesterolaemia: a sib pair and family analysis","volume":"6","author":"Lingenhel","year":"1998","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.jlr.2021.100062_bib60","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","article-title":"Lipoprotein(a) in homozygous familial hypercholesterolemia","volume":"20","author":"Kraft","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib61","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1172\/JCI119402","article-title":"Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB","volume":"99","author":"van der Hoek","year":"1997","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100062_bib62","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1253\/circj.CJ-15-0999","article-title":"Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutations","volume":"80","author":"Tada","year":"2016","journal-title":"Circ. J."},{"key":"10.1016\/j.jlr.2021.100062_bib63","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2021.100062_bib64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex\u00a0vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.jlr.2021.100062_bib65","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacbts.2020.03.008","article-title":"Lipoprotein(a) cellular uptake ex\u00a0vivo and hepatic capture in\u00a0vivo is insensitive to PCSK9 inhibition with alirocumab","volume":"5","author":"Chemello","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.jlr.2021.100062_bib66","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin. Sci. (Lond)."},{"key":"10.1016\/j.jlr.2021.100062_bib67","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2021.100062_bib68","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib69","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib70","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib72","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1021\/bi00011a037","article-title":"A\u00a0comparison of structure and thermal behavior in human plasma lipoprotein(a) and low-density lipoprotein. Calorimetry and small-angle X-ray scattering","volume":"34","author":"Prassl","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.jlr.2021.100062_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0009-3084(94)90127-9","article-title":"Electron-microscopic and hydrodynamic characterization of recombinant apolipoprotein (a) and its association with LDL","volume":"67","author":"Phillips","year":"1994","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jlr.2021.100062_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-pharmtox-010919-023545","article-title":"Cryo-Electron microscopy: moving beyond X-ray crystal structures for drug receptors and drug development","volume":"60","author":"Garc\u00eda-Nafr\u00eda","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jlr.2021.100062_bib75","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1073\/pnas.0908004107","article-title":"Model of human low-density lipoprotein and bound receptor based on CryoEM","volume":"107","author":"Ren","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jlr.2021.100062_bib76","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jlr.2021.100062_bib77","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2021.100062_bib78","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib79","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib80","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2006.02.023","article-title":"Association of heterozygous familial hypercholesterolemia with smaller HDL particle size","volume":"190","author":"Hogue","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib81","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/0026-0495(93)90138-E","article-title":"Insulin sensitivity in familial hypercholesterolemia","volume":"42","author":"Galvan","year":"1993","journal-title":"Metabolism"},{"key":"10.1016\/j.jlr.2021.100062_bib82","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1161\/01.CIR.97.9.871","article-title":"Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene","volume":"97","author":"Gaudet","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib83","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/ATVBAHA.111.227181","article-title":"Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia","volume":"31","author":"Bellanger","year":"2011","journal-title":"Arteriosclerosis, Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib84","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOL.0b013e328353ef07","article-title":"Reverse cholesterol transport in familial hypercholesterolemia","volume":"23","author":"Guerin","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100062_bib85","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.metabol.2013.02.008","article-title":"Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia","volume":"62","author":"Martinez","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.jlr.2021.100062_bib86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.plipres.2017.05.001","article-title":"HDL abnormalities in familial hypercholesterolemia: Focus on biological functions","volume":"67","author":"Ganjali","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib87","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0022-2275(20)33394-0","article-title":"Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study","volume":"40","author":"Fr\u00e9nais","year":"1999","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib88","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2006.10.035","article-title":"Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia","volume":"196","author":"Bouhali","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jlr.2021.100062_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2011.07.014","article-title":"Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box","volume":"61","author":"Chan","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.jlr.2021.100062_bib90","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13105-020-00753-1","article-title":"Cholesterol metabolism in mice models of genetic hypercholesterolemia","volume":"76","author":"Nunes","year":"2020","journal-title":"J.\u00a0Physiol. Biochem."},{"key":"10.1016\/j.jlr.2021.100062_bib91","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The Severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib92","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0022-2275(20)35728-X","article-title":"Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans","volume":"34","author":"Dietschy","year":"1993","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib93","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib94","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12944-017-0502-x","article-title":"The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels","volume":"16","author":"Drouin-Chartier","year":"2017","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jlr.2021.100062_bib95","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib96","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib97","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jlr.2021.100062_bib98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib99","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib100","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal Frederick","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib101","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/qjmed\/91.4.291","article-title":"High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia","volume":"91","author":"Wierzbicki","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.jlr.2021.100062_bib102","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1161\/01.ATV.17.8.1527","article-title":"Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia","volume":"17","author":"David","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.amjcard.2003.08.009","article-title":"Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia","volume":"92","author":"Stein","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","article-title":"Statins in homozygous familial hypercholesterolemia","volume":"4","author":"Marais","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jlr.2021.100062_bib105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/jcm9010219","article-title":"A\u00a0real-world experience of clinical, biochemical and genetic assessment of patients with homozygous familial hypercholesterolemia","volume":"9","author":"Di Taranto","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MOL.0b013e32834c7c28","article-title":"Intestinal sterol transporters and cholesterol absorption inhibition","volume":"22","author":"Davis","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2021.100062_bib107","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib108","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2014.07.004","article-title":"PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels","volume":"145","author":"Marais","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jlr.2021.100062_bib110","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jlr.2021.100062_bib111","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2021.100062_bib112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jlr.2021.100062_bib113","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jlr.2021.100062_bib114","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2021.100062_bib115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous FH patients with identical mutations variably express the LDL receptor: implications for the efficacy of evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib116","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in homozygous familial hypercholesterolemia","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2021.100062_bib118","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2021.100062_bib119","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2021.100062_bib120","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"24","author":"Rosenson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib121","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2021.100062_bib122","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/ATVBAHA.119.313051","article-title":"Functional analysis of ldlr (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity","volume":"39","author":"Banerjee","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jlr.2021.100062_bib123","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2021.100062_bib124","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijcard.2010.08.009","article-title":"Familial hypercholesterolemia and triglyceride metabolism","volume":"147","author":"Kolovou","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jlr.2021.100062_bib125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jlr.2021.100062_bib126","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1210\/jc.2016-2217","article-title":"\u03c9-3 Fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia","volume":"101","author":"Chan","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2021.100062_bib127","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jlr.2021.100062_bib128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227521000444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227521000444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T09:59:50Z","timestamp":1645091990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227521000444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":128,"alternative-id":["S0022227521000444"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2021.100062","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein metabolism in familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2021.100062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100062"}}